RC
AZN icon

Roundview Capital’s AstraZeneca AZN Stock Holding History

Roundview Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,513
Closed -$200K – 271
2022
Q2 		$200K Buy
+1,513
New +$199K 0.02% 275
2014
Q3 		– Sell
-15,769
Closed -$1.17M – 129
2014
Q2 		$1.17M Buy
+15,769
New +$1.14M 0.47% 77

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Roundview Capital's AZN Position: Q3 2022 in Review

Roundview Capital sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 1,513 shares — an estimated $200K sold.

Roundview Capital first reported a position in AZN in Q2 2014 and held it in 2 quarters. The position peaked at $1.17M in Q2 2014. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

  • Roundview Capital reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
  • Roundview Capital sold 1,513 AstraZeneca shares in Q3 2022, an estimated $200K.
  • Roundview Capital first reported a position in AstraZeneca in Q2 2014 and held it in 2 quarters.
  • Roundview Capital's AstraZeneca position peaked at $1.17M in Q2 2014.
  • 965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Roundview Capital's 13F filing for Q3 2022, filed 10 Nov 2022.